Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion
TipRanksApr 8 10:05 ET
Pharming Group's Strong Performance and Growth Prospects Justify Buy Rating
TipRanksMar 18 05:05 ET
Pharming Analyst Ratings
BenzingaMar 14 12:34 ET
Pharming Group's Strong Financial Performance and Growth Potential Merit Buy Rating
TipRanksMar 14 11:35 ET
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Pharming Group (OtherPHGUF)
TipRanksJan 11 20:50 ET
Pharming Group: Strong Buy Rating on Robust Revenue Growth and Promising Clinical Pipeline Expansion
TipRanksJan 8 06:26 ET
Pharming Group's Promising Clinical Trials and Regulatory Advancements Drive Analyst's Buy Rating
TipRanksNov 21, 2023 10:45 ET
Pharming Group (PHGUF) Receives a Buy From RBC Capital
TipRanksNov 8, 2023 20:48 ET
Pharming Group (PHAR) Gets a Buy From Oppenheimer
TipRanksOct 27, 2023 08:07 ET
Analysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM), Santhera Pharmaceuticals Holding (OtherSPHDF) and Pharming Group (OtherPHGUF)
TipRanksOct 27, 2023 06:31 ET
Pharming Group's Stock Positioned for Growth: Strong Performance of Ruconest and Promising Launch of Joenja Bolster Buy Rating
TipRanksOct 26, 2023 10:37 ET
RBC Capital Reaffirms Their Buy Rating on Pharming Group (PHGUF)
TipRanksSep 6, 2023 21:45 ET
H.C. Wainwright Keeps Their Buy Rating on Pharming Group (PHAR)
TipRanksAug 9, 2023 09:25 ET
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
BenzingaAug 3, 2023 13:12 ET
Pharming Analyst Ratings
BenzingaAug 3, 2023 13:11 ET
Analysts Offer Insights on Healthcare Companies: Pharming Group (PHAR), SurModics (SRDX) and REPRO-MED Systems (KRMD)
TipRanksAug 3, 2023 09:20 ET
RBC Capital Sticks to Their Buy Rating for Pharming Group (PHGUF)
TipRanksMay 15, 2023 21:45 ET
H.C. Wainwright Remains a Buy on Pharming Group (PHAR)
TipRanksMay 11, 2023 11:45 ET
Oppenheimer Maintains Outperform on Pharming, Raises Price Target to $40
BenzingaMar 28, 2023 09:58 ET
Oppenheimer Adjusts Pharming Group Price Target to $40 From $36, Maintains Outperform Rating
MT NewswiresMar 28, 2023 09:14 ET
No Data
No Data